{"protocolSection":{"identificationModule":{"nctId":"NCT02416453","orgStudyIdInfo":{"id":"CR107227"},"secondaryIdInfos":[{"id":"VAC52150EBL2001","type":"OTHER","domain":"Janssen Vaccines & Prevention B.V."},{"id":"2015-000596-27","type":"EUDRACT_NUMBER"},{"id":"2015","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2015"}],"organization":{"fullName":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"},"briefTitle":"A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults","officialTitle":"A Randomized, Observer-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Prime-Boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults in Europe"},"statusModule":{"statusVerifiedDate":"2021-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-06-15","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-01-19","type":"ACTUAL"},"completionDateStruct":{"date":"2018-01-19","type":"ACTUAL"},"studyFirstSubmitDate":"2015-04-10","studyFirstSubmitQcDate":"2015-04-10","studyFirstPostDateStruct":{"date":"2015-04-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-01-15","resultsFirstSubmitQcDate":"2021-01-15","resultsFirstPostDateStruct":{"date":"2021-02-08","type":"ACTUAL"},"dispFirstSubmitDate":"2019-01-17","dispFirstSubmitQcDate":"2019-01-17","dispFirstPostDateStruct":{"date":"2019-01-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-01-15","lastUpdatePostDateStruct":{"date":"2021-02-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"},"collaborators":[{"name":"Institut National de la Santé Et de la Recherche Médicale, France","class":"OTHER_GOV"},{"name":"University of Oxford","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of 3 vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens.","detailedDescription":"This is a randomized, observer-blind, placebo-controlled, parallel-group, multicenter, Phase 2 study evaluating the safety, tolerability and immunogenicity of 2-dose heterologous regimens using Ad26.ZEBOV and MVA-BN-Filo administered to healthy adults participants in Europe. The study involves a screening period of up to 12 weeks, a vaccination period in which participants will be vaccinated with Ad26.ZEBOV (dose 1) followed by vaccination with MVA-BN-Filo (dose 2) 28, 56 or 84 days later, and a post-vaccination phase until 6 months post dose 2 visit (Days 209, 237 or 265). After unblinding, only participants who received Ad26.ZEBOV and/or MVA-BN-Filo will continue the study until the Day 365 visit (or until the start of the roll-over study or for an additional 12 months \\[whichever comes first\\] for participants in France who agree to continue the long-term follow-up after Day 365) to assess long-term safety and immunogenicity. Participants will enroll into 3 cohorts: that is, Cohort 1 (Participants will receive Ad26.ZEBOV and MVA-BN-Filo in an open-label fashion), Cohort 2 (Participants will be randomized to receive the 2-dose heterologous vaccine regimen with either Ad26.ZEBOV followed by MVA-BN-Filo, or placebo in a 14:1 ratio) and Cohort 3 (Participants will be randomized to receive the 2-dose heterologous vaccine regimen with either Ad26.ZEBOV followed by MVA-BN-Filo, or placebo in a 10:3 ratio). In Cohorts 2 and 3, core immunogenicity assessments (humoral and cellular assays) will be performed. In Cohort 2, additional immunogenicity assessments will be done. In Cohort 1, plasma blast response kinetics will be evaluated. Safety will be monitored during the study."},"conditionsModule":{"conditions":["Ebola Viral Disease"],"keywords":["Healthy","Ebola viruses","Ebola Viral Disease (EVD)","Filoviruses","Monovalent vaccine","Human adenovirus serotype 26 (Ad26) encoding the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)","Modified Vaccinia Virus Ankara - Bavarian Nordic Filo-vector (MVA-BN Filo)","Safety","Immunogenicity","Inserm and University of Oxford"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":423,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group 1","type":"EXPERIMENTAL","description":"Participants will receive intramuscular (IM) injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 29.","interventionNames":["Biological: MVA-BN-Filo","Biological: Ad26.ZEBOV","Biological: Placebo"]},{"label":"Group 2","type":"EXPERIMENTAL","description":"Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 57.","interventionNames":["Biological: MVA-BN-Filo","Biological: Ad26.ZEBOV","Biological: Placebo"]},{"label":"Group 3","type":"EXPERIMENTAL","description":"Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 85.","interventionNames":["Biological: MVA-BN-Filo","Biological: Ad26.ZEBOV","Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"MVA-BN-Filo","description":"One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit \\[Inf. U.\\] on Day 29, 57, or 85.","armGroupLabels":["Group 1","Group 2","Group 3"]},{"type":"BIOLOGICAL","name":"Ad26.ZEBOV","description":"One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.","armGroupLabels":["Group 1","Group 2","Group 3"]},{"type":"BIOLOGICAL","name":"Placebo","description":"One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.","armGroupLabels":["Group 1","Group 2","Group 3"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Unsolicited Adverse Events (Groups 1, 2 and 3)","description":"An adverse event (AE) is any untoward medical occurrence in a clinical study subject administered a medicinal product, it does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal product. Unsolicited adverse events were events which were reported by the participant voluntarily or obtained by means of interviewing the participant in a nondirected manner at study visits.","timeFrame":"Up to 42-day post dose 2 visit (Day 1 to Day 127)"},{"measure":"Number of Participants With Serious Adverse Events (Groups 1, 2 and 3)","description":"A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","timeFrame":"Up to Day 365"},{"measure":"Number of Participants With Immediate Reportable Events (Groups 1, 2 and 3)","description":"The following neuroinflammatory disorders were considered immediate reportable events and which had to be reported to the sponsor within 24 hours of becoming aware of the event. Neuroinflammatory disorders included: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), myasthenia gravis and lambert-eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, including chronic inflammatory, demyelinating polyneuropathy, multifocal motor neuropathy, and polyneuropathies associated with monoclonal gammopathy, narcolepsy, isolated paresthesia of more than 7 days duration.","timeFrame":"Up to Day 365"},{"measure":"Number of Participants With Solicited Local Adverse Events (Groups 1, 2 and 3)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","timeFrame":"7 days post-dose 1 (Day 8)"},{"measure":"Number of Participants With Solicited Local Adverse Events (Groups 1, 2 and 3)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","timeFrame":"7 days post-dose 2 (Up to Day 92)"},{"measure":"Number of Participants With Solicited Systemic Adverse Events (Groups 1, 2 and 3)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","timeFrame":"7 days post-dose 1 (Day 8)"},{"measure":"Number of Participants With Solicited Systemic Adverse Events (Groups 1, 2 and 3)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","timeFrame":"7 days post-dose 2 (Up to Day 92)"}],"secondaryOutcomes":[{"measure":"Number of Participants With Unsolicited Adverse Events (Group 4)","description":"An AE is any untoward medical occurrence in a clinical study subject administered a medicinal product, it does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal product. Unsolicited adverse events were events which were reported by the participant voluntarily or obtained by means of interviewing the participant in a nondirected manner at study visits.","timeFrame":"Up to 28-day post dose 1 (Day 29)"},{"measure":"Number of Participants With Serious Adverse Events (Group 4)","description":"A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","timeFrame":"Up to Day 180"},{"measure":"Number of Participants With Immediate Reportable Events (Group 4)","description":"The following neuroinflammatory disorders were considered immediate reportable events which had to be reported to the sponsor within 24 hours of becoming aware of the event. Neuroinflammatory disorders included: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), myasthenia gravis and lambert-eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, including chronic inflammatory, demyelinating polyneuropathy, multifocal motor neuropathy, and polyneuropathies associated with monoclonal gammopathy, narcolepsy, isolated paresthesia of more than 7 days duration.","timeFrame":"Up to Day 180"},{"measure":"Number of Participants With Solicited Local Adverse Events (Group 4)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","timeFrame":"7 days after each vaccination (Up to Day 8)"},{"measure":"Number of Participants With Solicited Systemic Adverse Events (Group 4)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","timeFrame":"7 days after each vaccination (Up to Day 8)"},{"measure":"Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against Ebola Virus Glycoprotein (EBOV GP) Measured Using Filovirus Animal Non-Clinical Group (FANG) Enzyme-linked Immunosorbent Assay (ELISA) (Groups 1, 2 and 3)","description":"GMCs of antibodies binding to EBOV GP using FANG ELISA were reported and were measured in ELISA unit per milliliter (EU/mL). Serum samples were collected for analysis of binding antibodies against EBOV GP using FANG ELISA to determine humoral responses following vaccination. For ELISA binding antibody responses, values below the lower limit of quantification (LLOQ) (36.11 ELISA units/mL). The outcome measure was planned to be reported at 21-day post dose 2. Therefore, the results are reported for Group 1, 2 and 3 only.","timeFrame":"At 21-days post dose 2 (Day 50 for Group 1; Day 78 for Group 2; and Day 106 for Group 3)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must be healthy in the Investigator's clinical judgment on the basis of medical history, physical examination, electrocardiogram (ECG) and vital signs performed at Screening\n* Must be healthy on the basis of clinical laboratory tests performed at Screening. If the results of the laboratory screening tests are outside the normal reference ranges, the participant may be included only if the Investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study\n* Before randomization, a woman must be either of childbearing potential and practicing (or intending to practice) a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for participants participating in clinical studies, beginning at least 28 days prior to vaccination OR not of childbearing potential: postmenopausal (greater than \\[\\>\\] 45 years of age with amenorrhea for at least 2 years or lesser than or equal to \\[\\<=\\] 45 years of age with amenorrhea for at least 6 months, and a serum follicle stimulating hormone (FSH) level \\>40 international unit per milliliter \\[IU/L\\]); permanently sterilized (for example, bilateral tubal occlusion \\[which includes tubal ligation procedures as consistent with local regulations\\], hysterectomy, bilateral salpingectomy, bilateral oophorectomy); or otherwise be incapable of pregnancy\n* Woman of childbearing potential must have a negative serum (beta-human chorionic gonadotropin \\[beta-hCG\\]) at Screening and a negative urine beta-hCG pregnancy test immediately prior to each study vaccine administration\n* Man who is sexually active with a woman of childbearing potential and has not had a vasectomy performed more than 1 year prior to screening must be willing to use condoms for sexual intercourse beginning prior to enrollment\n\nExclusion Criteria:\n\n* Having received any candidate Ebola vaccine\n* Diagnosed with Ebola virus disease, or prior exposure to Ebola virus, including travel to West Africa less than 1 month prior to screening. West Africa includes but is not limited to the countries of Guinea, Liberia, Mali, and Sierra Leone\n* Having received any experimental candidate adenovirus serotype 26 (vector: Ad26) or Modified Vaccinia Ankara (MVA-) based vaccine in the past\n* Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine products (including any of the constituents of the study vaccines including known allergy to egg, egg products and aminoglycosides\n* Presence of acute illness or temperature greater than or equal to 38.0 C on Day 1","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Janssen Vaccines & Prevention B.V. Clinical Trial","affiliation":"Janssen Vaccines & Prevention B.V.","role":"STUDY_DIRECTOR"},{"name":"Inserm Clinical Trials","affiliation":"Institut National de la Santé Et de la Recherche Médicale, France","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Créteil","country":"France","geoPoint":{"lat":48.79266,"lon":2.46569}},{"city":"Marseille","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"city":"Paris","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"city":"Pierre-Bénite","country":"France","geoPoint":{"lat":45.70359,"lon":4.82424}},{"city":"Rennes","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"city":"Saint-Etienne","country":"France","geoPoint":{"lat":45.43389,"lon":4.39}},{"city":"Strasbourg","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"city":"Tours","country":"France","geoPoint":{"lat":47.39484,"lon":0.70398}},{"city":"London","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"city":"Oxford","country":"United Kingdom","geoPoint":{"lat":51.75222,"lon":-1.25596}},{"city":"Southampton","country":"United Kingdom","geoPoint":{"lat":50.90395,"lon":-1.40428}}]},"referencesModule":{"references":[{"pmid":"39012798","type":"DERIVED","citation":"Lacabaratz C, Durand M, Wiedemann A, Foucat E, Surenaud M, Krief C, Guillaumat L, Robinson C, Luhn K, Bockstal V, Thiebaut R, Richert L, Levy Y. Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial. J Infect Dis. 2025 Feb 4;231(1):230-240. doi: 10.1093/infdis/jiae360."},{"pmid":"38603720","type":"DERIVED","citation":"Barry H, Lhomme E, Surenaud M, Nouctara M, Robinson C, Bockstal V, Valea I, Somda S, Tinto H, Meda N, Greenwood B, Thiebaut R, Lacabaratz C. Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen. PLoS Negl Trop Dis. 2024 Apr 11;18(4):e0011500. doi: 10.1371/journal.pntd.0011500. eCollection 2024 Apr."},{"pmid":"33217361","type":"DERIVED","citation":"Pollard AJ, Launay O, Lelievre JD, Lacabaratz C, Grande S, Goldstein N, Robinson C, Gaddah A, Bockstal V, Wiedemann A, Leyssen M, Luhn K, Richert L, Betard C, Gibani MM, Clutterbuck EA, Snape MD, Levy Y, Douoguih M, Thiebaut R; EBOVAC2 EBL2001 study group. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2021 Apr;21(4):493-506. doi: 10.1016/S1473-3099(20)30476-X. Epub 2020 Nov 17."}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"A total of 423 participants were randomized (408 participants in Groups 1 to 3 and 15 participants in Group 4). Among them, 421 participants received at least one dose of study vaccines. Two participants were randomized but not vaccinated.","groups":[{"id":"FG000","title":"Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5\\*10\\^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29."},{"id":"FG001","title":"Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"FG002","title":"Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"FG003","title":"Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 29."},{"id":"FG004","title":"Group 1: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 29."},{"id":"FG005","title":"Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"FG006","title":"Group 2: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 57."},{"id":"FG007","title":"Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"FG008","title":"Group 3: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 85."},{"id":"FG009","title":"Group 4: Ad26.ZEBOV","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp on Day 1."},{"id":"FG010","title":"Group 4: Placebo","description":"Participants received IM injection of placebo Day 1."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"112"},{"groupId":"FG004","numSubjects":"13"},{"groupId":"FG005","numSubjects":"114"},{"groupId":"FG006","numSubjects":"13"},{"groupId":"FG007","numSubjects":"106"},{"groupId":"FG008","numSubjects":"18"},{"groupId":"FG009","numSubjects":"13"},{"groupId":"FG010","numSubjects":"2"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"97"},{"groupId":"FG004","numSubjects":"12"},{"groupId":"FG005","numSubjects":"98"},{"groupId":"FG006","numSubjects":"11"},{"groupId":"FG007","numSubjects":"94"},{"groupId":"FG008","numSubjects":"13"},{"groupId":"FG009","numSubjects":"13"},{"groupId":"FG010","numSubjects":"2"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"15"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"16"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"5"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"8"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"8"},{"groupId":"FG008","numSubjects":"4"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"}]},{"type":"PARTICIPANT UNABLE TO ATTEND ANY FURTHER","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"}]},{"type":"PARTICIPANT HAS MOVED TO SINGAPORE","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5\\*10\\^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29."},{"id":"BG001","title":"Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"BG002","title":"Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"BG003","title":"Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 29."},{"id":"BG004","title":"Group 1: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 29."},{"id":"BG005","title":"Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"BG006","title":"Group 2: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 57."},{"id":"BG007","title":"Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"BG008","title":"Group 3: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 85."},{"id":"BG009","title":"Group 4: Ad26.ZEBOV","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp on Day 1."},{"id":"BG010","title":"Group 4: Placebo","description":"Participants received IM injection of placebo Day 1."},{"id":"BG011","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"112"},{"groupId":"BG004","value":"13"},{"groupId":"BG005","value":"114"},{"groupId":"BG006","value":"13"},{"groupId":"BG007","value":"106"},{"groupId":"BG008","value":"18"},{"groupId":"BG009","value":"13"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"421"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34.2","spread":"12.95"},{"groupId":"BG001","value":"47.4","spread":"16.53"},{"groupId":"BG002","value":"38.7","spread":"13.99"},{"groupId":"BG003","value":"41","spread":"15"},{"groupId":"BG004","value":"39.1","spread":"13.9"},{"groupId":"BG005","value":"41","spread":"14.02"},{"groupId":"BG006","value":"38.2","spread":"13.66"},{"groupId":"BG007","value":"38.3","spread":"14.34"},{"groupId":"BG008","value":"41.1","spread":"15.11"},{"groupId":"BG009","value":"37.9","spread":"11.37"},{"groupId":"BG010","value":"47","spread":"4.24"},{"groupId":"BG011","value":"40","spread":"14.32"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"57"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"62"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"53"},{"groupId":"BG008","value":"10"},{"groupId":"BG009","value":"3"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"217"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"55"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"52"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"53"},{"groupId":"BG008","value":"8"},{"groupId":"BG009","value":"10"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"204"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"13"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"3"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"36"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"97"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"102"},{"groupId":"BG006","value":"10"},{"groupId":"BG007","value":"89"},{"groupId":"BG008","value":"16"},{"groupId":"BG009","value":"10"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"365"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"3"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"4"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"France","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"54"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"55"},{"groupId":"BG006","value":"7"},{"groupId":"BG007","value":"50"},{"groupId":"BG008","value":"9"},{"groupId":"BG009","value":"13"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"197"}]}]},{"title":"United Kingdom","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"58"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"59"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"56"},{"groupId":"BG008","value":"9"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"224"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Unsolicited Adverse Events (Groups 1, 2 and 3)","description":"An adverse event (AE) is any untoward medical occurrence in a clinical study subject administered a medicinal product, it does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal product. Unsolicited adverse events were events which were reported by the participant voluntarily or obtained by means of interviewing the participant in a nondirected manner at study visits.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 42-day post dose 2 visit (Day 1 to Day 127)","groups":[{"id":"OG000","title":"Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5\\*10\\^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29."},{"id":"OG001","title":"Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"OG002","title":"Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"OG003","title":"Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 29."},{"id":"OG004","title":"Group 1: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 29."},{"id":"OG005","title":"Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"OG006","title":"Group 2: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 57."},{"id":"OG007","title":"Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"OG008","title":"Group 3: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 85."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"112"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"114"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"106"},{"groupId":"OG008","value":"18"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"62"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"52"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"46"},{"groupId":"OG008","value":"8"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events (Groups 1, 2 and 3)","description":"A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 365","groups":[{"id":"OG000","title":"Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5\\*10\\^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29."},{"id":"OG001","title":"Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"OG002","title":"Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"OG003","title":"Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 29."},{"id":"OG004","title":"Group 1: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 29."},{"id":"OG005","title":"Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"OG006","title":"Group 2: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 57."},{"id":"OG007","title":"Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"OG008","title":"Group 3: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 85."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"112"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"114"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"106"},{"groupId":"OG008","value":"18"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"1"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Immediate Reportable Events (Groups 1, 2 and 3)","description":"The following neuroinflammatory disorders were considered immediate reportable events and which had to be reported to the sponsor within 24 hours of becoming aware of the event. Neuroinflammatory disorders included: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), myasthenia gravis and lambert-eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, including chronic inflammatory, demyelinating polyneuropathy, multifocal motor neuropathy, and polyneuropathies associated with monoclonal gammopathy, narcolepsy, isolated paresthesia of more than 7 days duration.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 365","groups":[{"id":"OG000","title":"Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5\\*10\\^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29."},{"id":"OG001","title":"Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"OG002","title":"Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"OG003","title":"Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 29."},{"id":"OG004","title":"Group 1: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 29."},{"id":"OG005","title":"Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"OG006","title":"Group 2: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 57."},{"id":"OG007","title":"Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"OG008","title":"Group 3: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 85."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"112"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"114"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"106"},{"groupId":"OG008","value":"18"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Local Adverse Events (Groups 1, 2 and 3)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days post-dose 1 (Day 8)","groups":[{"id":"OG000","title":"Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5\\*10\\^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29."},{"id":"OG001","title":"Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"OG002","title":"Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"OG003","title":"Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 29."},{"id":"OG004","title":"Group 1: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 29."},{"id":"OG005","title":"Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"OG006","title":"Group 2: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 57."},{"id":"OG007","title":"Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"OG008","title":"Group 3: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 85."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"112"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"114"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"106"},{"groupId":"OG008","value":"18"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"63"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"65"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"78"},{"groupId":"OG008","value":"4"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Local Adverse Events (Groups 1, 2 and 3)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days post-dose 2 (Up to Day 92)","groups":[{"id":"OG000","title":"Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5\\*10\\^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29."},{"id":"OG001","title":"Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"OG002","title":"Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"OG003","title":"Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 29."},{"id":"OG004","title":"Group 1: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 29."},{"id":"OG005","title":"Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"OG006","title":"Group 2: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 57."},{"id":"OG007","title":"Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"OG008","title":"Group 3: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 85."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"91"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"83"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"62"},{"groupId":"OG008","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"49"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"41"},{"groupId":"OG008","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Systemic Adverse Events (Groups 1, 2 and 3)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days post-dose 1 (Day 8)","groups":[{"id":"OG000","title":"Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5\\*10\\^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29."},{"id":"OG001","title":"Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"OG002","title":"Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"OG003","title":"Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 29."},{"id":"OG004","title":"Group 1: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 29."},{"id":"OG005","title":"Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"OG006","title":"Group 2: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 57."},{"id":"OG007","title":"Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"OG008","title":"Group 3: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 85."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"112"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"114"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"106"},{"groupId":"OG008","value":"18"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"89"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"84"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"82"},{"groupId":"OG008","value":"7"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Systemic Adverse Events (Groups 1, 2 and 3)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days post-dose 2 (Up to Day 92)","groups":[{"id":"OG000","title":"Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5\\*10\\^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29."},{"id":"OG001","title":"Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"OG002","title":"Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"OG003","title":"Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 29."},{"id":"OG004","title":"Group 1: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 29."},{"id":"OG005","title":"Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"OG006","title":"Group 2: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 57."},{"id":"OG007","title":"Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"OG008","title":"Group 3: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 85."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"91"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"83"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"62"},{"groupId":"OG008","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"42"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"36"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"38"},{"groupId":"OG008","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Unsolicited Adverse Events (Group 4)","description":"An AE is any untoward medical occurrence in a clinical study subject administered a medicinal product, it does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal product. Unsolicited adverse events were events which were reported by the participant voluntarily or obtained by means of interviewing the participant in a nondirected manner at study visits.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 28-day post dose 1 (Day 29)","groups":[{"id":"OG000","title":"Group 4: Ad26.ZEBOV","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp on Day 1."},{"id":"OG001","title":"Group 4: Placebo","description":"Participants received IM injection of placebo Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"2"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events (Group 4)","description":"A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 180","groups":[{"id":"OG000","title":"Group 4: Ad26.ZEBOV","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp on Day 1."},{"id":"OG001","title":"Group 4: Placebo","description":"Participants received IM injection of placebo Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"2"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Immediate Reportable Events (Group 4)","description":"The following neuroinflammatory disorders were considered immediate reportable events which had to be reported to the sponsor within 24 hours of becoming aware of the event. Neuroinflammatory disorders included: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), myasthenia gravis and lambert-eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, including chronic inflammatory, demyelinating polyneuropathy, multifocal motor neuropathy, and polyneuropathies associated with monoclonal gammopathy, narcolepsy, isolated paresthesia of more than 7 days duration.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 180","groups":[{"id":"OG000","title":"Group 4: Ad26.ZEBOV","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp on Day 1."},{"id":"OG001","title":"Group 4: Placebo","description":"Participants received IM injection of placebo Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"2"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Solicited Local Adverse Events (Group 4)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days after each vaccination (Up to Day 8)","groups":[{"id":"OG000","title":"Group 4: Ad26.ZEBOV","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp on Day 1."},{"id":"OG001","title":"Group 4: Placebo","description":"Participants received IM injection of placebo Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"2"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Solicited Systemic Adverse Events (Group 4)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days after each vaccination (Up to Day 8)","groups":[{"id":"OG000","title":"Group 4: Ad26.ZEBOV","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp on Day 1."},{"id":"OG001","title":"Group 4: Placebo","description":"Participants received IM injection of placebo Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"2"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against Ebola Virus Glycoprotein (EBOV GP) Measured Using Filovirus Animal Non-Clinical Group (FANG) Enzyme-linked Immunosorbent Assay (ELISA) (Groups 1, 2 and 3)","description":"GMCs of antibodies binding to EBOV GP using FANG ELISA were reported and were measured in ELISA unit per milliliter (EU/mL). Serum samples were collected for analysis of binding antibodies against EBOV GP using FANG ELISA to determine humoral responses following vaccination. For ELISA binding antibody responses, values below the lower limit of quantification (LLOQ) (36.11 ELISA units/mL). The outcome measure was planned to be reported at 21-day post dose 2. Therefore, the results are reported for Group 1, 2 and 3 only.","populationDescription":"The per protocol analysis set included all randomized and vaccinated participants, who received both the prime and boost vaccinations (administered within the protocol-defined window), have at least 1 post-vaccination (that is, after the date of vaccination) evaluable immunogenicity sample, and have no major protocol violations influencing the immune response. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/mL","timeFrame":"At 21-days post dose 2 (Day 50 for Group 1; Day 78 for Group 2; and Day 106 for Group 3)","groups":[{"id":"OG000","title":"Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 29."},{"id":"OG001","title":"Group 1: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 29."},{"id":"OG002","title":"Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57."},{"id":"OG003","title":"Group 2: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 57."},{"id":"OG004","title":"Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85."},{"id":"OG005","title":"Group 3: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 85."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"69"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"48"},{"groupId":"OG005","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4627","lowerLimit":"3649","upperLimit":"5867"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"55","comment":"Here, 'NA' signifies that Geometric mean and lower limit of 95% CI were not calculated because post dose values were less than LLOQ (36.11 ELISA units/mL)."},{"groupId":"OG002","value":"10131","lowerLimit":"8554","upperLimit":"11999"},{"groupId":"OG003","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Here, 'NA' signifies that Geometric mean and CI were not calculated because post dose values were less than LLOQ (36.11 ELISA units/mL)."},{"groupId":"OG004","value":"11312","lowerLimit":"9072","upperLimit":"14106"},{"groupId":"OG005","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Here, 'NA' signifies that Geometric mean and CI were not calculated because post dose values were less than LLOQ (36.11 ELISA units/mL)."}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to Day 365","description":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.","eventGroups":[{"id":"EG000","title":"Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5\\*10\\^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":4,"otherNumAtRisk":10},{"id":"EG001","title":"Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":1,"seriousNumAtRisk":10,"otherNumAffected":5,"otherNumAtRisk":10},{"id":"EG002","title":"Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":6,"otherNumAtRisk":10},{"id":"EG003","title":"Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 29.","deathsNumAffected":0,"deathsNumAtRisk":112,"seriousNumAffected":2,"seriousNumAtRisk":112,"otherNumAffected":41,"otherNumAtRisk":112},{"id":"EG004","title":"Group 1: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 29.","deathsNumAffected":0,"deathsNumAtRisk":13,"seriousNumAffected":0,"seriousNumAtRisk":13,"otherNumAffected":6,"otherNumAtRisk":13},{"id":"EG005","title":"Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 57.","deathsNumAffected":0,"deathsNumAtRisk":114,"seriousNumAffected":4,"seriousNumAtRisk":114,"otherNumAffected":30,"otherNumAtRisk":114},{"id":"EG006","title":"Group 2: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 57.","deathsNumAffected":0,"deathsNumAtRisk":13,"seriousNumAffected":1,"seriousNumAtRisk":13,"otherNumAffected":7,"otherNumAtRisk":13},{"id":"EG007","title":"Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1\\*10\\^8 Inf.U (nominal titer) as dose 2 on Day 85.","deathsNumAffected":0,"deathsNumAtRisk":106,"seriousNumAffected":5,"seriousNumAtRisk":106,"otherNumAffected":26,"otherNumAtRisk":106},{"id":"EG008","title":"Group 3: Pooled Cohorts II and III: Placebo","description":"Participants received IM injection of placebo on Day 1 and Day 85.","deathsNumAffected":0,"deathsNumAtRisk":18,"seriousNumAffected":1,"seriousNumAtRisk":18,"otherNumAffected":8,"otherNumAtRisk":18},{"id":"EG009","title":"Group 4: Ad26.ZEBOV","description":"Participants received IM injection of Ad26.ZEBOV at 5\\*10\\^10 vp on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":13,"seriousNumAffected":2,"seriousNumAtRisk":13,"otherNumAffected":6,"otherNumAtRisk":13},{"id":"EG010","title":"Group 4: Placebo","description":"Participants received IM injection of placebo Day 1.","deathsNumAffected":0,"deathsNumAtRisk":2,"seriousNumAffected":0,"seriousNumAtRisk":2,"otherNumAffected":1,"otherNumAtRisk":2}],"seriousEvents":[{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":1,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":1,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Food allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":1,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":1,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Chronic sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Hepatitis A","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Human papilloma virus test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":1,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Osteosarcoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":1,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Cerebral venous thrombosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":1,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Miller Fisher syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Small fibre neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":1,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Abortion spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":1,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Appendicectomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]}],"otherEvents":[{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Dental discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":114},{"groupId":"EG006","numAffected":1,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":1,"numAtRisk":106},{"groupId":"EG008","numAffected":1,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":2,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":2,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":1,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":1,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":1,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":1,"numAtRisk":106},{"groupId":"EG008","numAffected":1,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Application site bruise","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":1,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":1,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":2,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":1,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":1,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":3,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":1,"numAtRisk":13},{"groupId":"EG007","numAffected":1,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":1,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":7,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":6,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":3,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":6,"numAtRisk":112},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":6,"numAtRisk":114},{"groupId":"EG006","numAffected":1,"numAtRisk":13},{"groupId":"EG007","numAffected":3,"numAtRisk":106},{"groupId":"EG008","numAffected":1,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":112},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":112},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":1,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":3,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":3,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":3,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":2,"numAtRisk":10},{"groupId":"EG003","numAffected":3,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":2,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":2,"numAtRisk":106},{"groupId":"EG008","numAffected":1,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Prothrombin time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":114},{"groupId":"EG006","numAffected":1,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":114},{"groupId":"EG006","numAffected":1,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":1,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":3,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":114},{"groupId":"EG006","numAffected":1,"numAtRisk":13},{"groupId":"EG007","numAffected":3,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":2,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Chondropathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":1,"numAtRisk":2}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":1,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":1,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Dizziness postural","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":1,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":1,"numAtRisk":106},{"groupId":"EG008","numAffected":1,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":3,"numAtRisk":112},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":3,"numAtRisk":114},{"groupId":"EG006","numAffected":1,"numAtRisk":13},{"groupId":"EG007","numAffected":5,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":2,"numAtRisk":114},{"groupId":"EG006","numAffected":1,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":4,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":114},{"groupId":"EG006","numAffected":2,"numAtRisk":13},{"groupId":"EG007","numAffected":3,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":1,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":112},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":114},{"groupId":"EG006","numAffected":0,"numAtRisk":13},{"groupId":"EG007","numAffected":0,"numAtRisk":106},{"groupId":"EG008","numAffected":0,"numAtRisk":18},{"groupId":"EG009","numAffected":0,"numAtRisk":13},{"groupId":"EG010","numAffected":0,"numAtRisk":2}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days."},"pointOfContact":{"title":"Medical Leader","organization":"Janssen Research & Development, LLC","email":"ClinicalTrialDisclosure@its.jnj.com","phone":"844-434-4210"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-05-30","uploadDate":"2021-01-15T09:56","filename":"SAP_000.pdf","size":986539},{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2017-04-20","uploadDate":"2021-01-15T09:56","filename":"Prot_001.pdf","size":1766172}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"}},"hasResults":true}